Logo image of COGT

COGENT BIOSCIENCES INC (COGT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:COGT - US19240Q2012 - Common Stock

39.73 USD
-0.44 (-1.1%)
Last: 12/24/2025, 5:00:00 PM
39.55 USD
-0.18 (-0.45%)
After Hours: 12/24/2025, 5:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to COGT. COGT was compared to 530 industry peers in the Biotechnology industry. COGT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. COGT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year COGT has reported negative net income.
In the past year COGT has reported a negative cash flow from operations.
In the past 5 years COGT always reported negative net income.
COGT had a negative operating cash flow in each of the past 5 years.
COGT Yearly Net Income VS EBIT VS OCF VS FCFCOGT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

COGT has a Return On Assets of -50.42%. This is comparable to the rest of the industry: COGT outperforms 49.25% of its industry peers.
The Return On Equity of COGT (-71.01%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -50.42%
ROE -71.01%
ROIC N/A
ROA(3y)-52.46%
ROA(5y)-51.99%
ROE(3y)-64.47%
ROE(5y)-60.7%
ROIC(3y)N/A
ROIC(5y)N/A
COGT Yearly ROA, ROE, ROICCOGT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for COGT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COGT Yearly Profit, Operating, Gross MarginsCOGT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

COGT has more shares outstanding than it did 1 year ago.
COGT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for COGT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
COGT Yearly Shares OutstandingCOGT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COGT Yearly Total Debt VS Total AssetsCOGT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 29.21 indicates that COGT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 29.21, COGT belongs to the top of the industry, outperforming 92.45% of the companies in the same industry.
A Debt/Equity ratio of 0.15 indicates that COGT is not too dependend on debt financing.
The Debt to Equity ratio of COGT (0.15) is worse than 65.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 29.21
ROIC/WACCN/A
WACCN/A
COGT Yearly LT Debt VS Equity VS FCFCOGT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 6.38 indicates that COGT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.38, COGT is in the better half of the industry, outperforming 65.09% of the companies in the same industry.
A Quick Ratio of 6.38 indicates that COGT has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.38, COGT is doing good in the industry, outperforming 66.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.38
Quick Ratio 6.38
COGT Yearly Current Assets VS Current LiabilitesCOGT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.66% over the past year.
EPS 1Y (TTM)32.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 26.33% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-16.37%
EPS Next 2Y5.49%
EPS Next 3Y21.85%
EPS Next 5Y26.33%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
COGT Yearly Revenue VS EstimatesCOGT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
COGT Yearly EPS VS EstimatesCOGT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

COGT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for COGT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COGT Price Earnings VS Forward Price EarningsCOGT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COGT Per share dataCOGT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as COGT's earnings are expected to grow with 21.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.49%
EPS Next 3Y21.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for COGT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

COGENT BIOSCIENCES INC

NASDAQ:COGT (12/24/2025, 5:00:00 PM)

After market: 39.55 -0.18 (-0.45%)

39.73

-0.44 (-1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/bmo
Earnings (Next)02-23 2026-02-23/amc
Inst Owners91.6%
Inst Owner Change12.86%
Ins Owners0.03%
Ins Owner Change68.04%
Market Cap6.96B
Revenue(TTM)N/A
Net Income(TTM)-214.77M
Analysts85.56
Price Target50.07 (26.03%)
Short Float %8.09%
Short Ratio4.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.27%
Min EPS beat(2)7.11%
Max EPS beat(2)11.44%
EPS beat(4)4
Avg EPS beat(4)27.89%
Min EPS beat(4)7.11%
Max EPS beat(4)80.14%
EPS beat(8)4
Avg EPS beat(8)8.84%
EPS beat(12)5
Avg EPS beat(12)3.36%
EPS beat(16)6
Avg EPS beat(16)-1.05%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.06%
PT rev (3m)143.02%
EPS NQ rev (1m)0.5%
EPS NQ rev (3m)-2.03%
EPS NY rev (1m)-1.17%
EPS NY rev (3m)-7.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 23.02
P/tB 23.02
EV/EBITDA N/A
EPS(TTM)-1.67
EYN/A
EPS(NY)-1.75
Fwd EYN/A
FCF(TTM)-1.41
FCFYN/A
OCF(TTM)-1.4
OCFYN/A
SpS0
BVpS1.73
TBVpS1.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.42%
ROE -71.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.46%
ROA(5y)-51.99%
ROE(3y)-64.47%
ROE(5y)-60.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.38
Quick Ratio 6.38
Altman-Z 29.21
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)321.08%
Cap/Depr(5y)421.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.88%
EPS Next Y-16.37%
EPS Next 2Y5.49%
EPS Next 3Y21.85%
EPS Next 5Y26.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.88%
EBIT Next 3Y7.84%
EBIT Next 5Y26.11%
FCF growth 1Y-72.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-76.97%
OCF growth 3YN/A
OCF growth 5YN/A

COGENT BIOSCIENCES INC / COGT FAQ

What is the fundamental rating for COGT stock?

ChartMill assigns a fundamental rating of 2 / 10 to COGT.


What is the valuation status of COGENT BIOSCIENCES INC (COGT) stock?

ChartMill assigns a valuation rating of 1 / 10 to COGENT BIOSCIENCES INC (COGT). This can be considered as Overvalued.


What is the profitability of COGT stock?

COGENT BIOSCIENCES INC (COGT) has a profitability rating of 1 / 10.